Home / Business and Economy / Pharma Director Sells $977K in Arrowhead Stock
Pharma Director Sells $977K in Arrowhead Stock
7 Sep
Summary
- Director Michael S. Perry sold 11,600 shares on Aug. 18, 2026.
- The sale represented 9% of the director's direct holdings.
- Arrowhead Pharmaceuticals has a $12.2 billion market cap.
On August 18, 2026, Michael S. Perry, a Director at Arrowhead Pharmaceuticals, divested 11,600 shares of common stock. This sale, executed at prices between $87.20 and $87.44, resulted in a liquidation of 9% of his direct holdings.
Perry continues to hold a stake representing 0.0791% of the company's equity. This transaction occurred as Arrowhead Pharmaceuticals, headquartered in Pasadena, California, boasts a market capitalization of $12.2 billion. The company focuses on developing RNA interference (RNAi) therapies for challenging diseases.